This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Is Cardinal Health (CAH) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Prescription for Profits: 3 Must-Buy Healthcare Stocks Before 2025
by Kaibalya Pravo Dey
The healthcare sector is undergoing significant changes, with technology, innovation and a patient-centric approach as the cornerstones of its growth.
Best Growth Stocks to Buy for December 16th
by Zacks Equity Research
ZIM, MCK and GBX made it to the Zacks Rank #1 (Strong Buy) growth stocks list on December 16, 2024
Best Value Stocks to Buy for December 16th
by Zacks Equity Research
ZIM, MCK and DFH made it to the Zacks Rank #1 (Strong Buy) value stocks list on December 16, 2024.
Zacks Industry Outlook Becton, Dickinson, BD, McKesson, Cardinal Health and Merit Medical Systems
by Zacks Equity Research
Becton, Dickinson, BD, McKesson, Cardinal Health and Merit Medical Systems have been highlighted in this Industry Outlook article.
McKesson (MCK) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the most recent trading session, McKesson (MCK) closed at $579.29, indicating a +0.45% shift from the previous trading day.
Here's Why McKesson (MCK) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
4 Stocks to Watch Amid Dental Supplies Industry Challenges
by Indrajit Bandyopadhyay
Here we discuss four stocks from the Dental Supplies industry that are likely to earn wealth for investors. These are BDX, MCK, CAH and MMSI.
McKesson Corporation (MCK) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Zacks.com users have recently been watching McKesson (MCK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
McKesson Corporation (MCK) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to McKesson (MCK). This makes it worthwhile to examine what the stock has in store.
Why McKesson (MCK) is a Top Value Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
McKesson Stock Gains 34.1% YTD: What's Driving the Rally?
by Zacks Equity Research
MCK continues to gain because of robust segmental performance and raised fiscal 2025 guidance.
MCK Stock Down Despite Latest Partnership to Boost SCD Treatment
by Zacks Equity Research
The availability of the FDA-approved drug via McKesson's cell and gene therapies business is expected to give patients improved treatment options for SCD.
All You Need to Know About McKesson (MCK) Rating Upgrade to Buy
by Zacks Equity Research
McKesson (MCK) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Are Investors Undervaluing Cardinal Health (CAH) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
McKesson (MCK) Is Considered a Good Investment by Brokers: Is That True?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in McKesson (MCK). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Investors Heavily Search McKesson Corporation (MCK): Here is What You Need to Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to McKesson (MCK). This makes it worthwhile to examine what the stock has in store.
Here is Why Growth Investors Should Buy McKesson (MCK) Now
by Zacks Equity Research
McKesson (MCK) possesses solid growth attributes, which could help it handily outperform the market.
Here's Why McKesson (MCK) is a Strong Momentum Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
5 Stocks That Look Promising Following Broker Rating Upgrades
by Maharathi Basu
Investors should monitor stocks like American Airlines, Air Canada, DXC, Dollar General, and McKesson for high returns.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
MCK Stock Gains as Q2 Earnings & Sales Top Estimates, '25 EPS View Up
by Zacks Equity Research
McKesson's second-quarter fiscal 2025 results showcase growth in the U.S. Pharmaceutical segment. However, Medical Surgical Solutions suffers due to lower COVID-related sales.
McKesson (MCK) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
Although the revenue and EPS for McKesson (MCK) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
McKesson (MCK) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
McKesson (MCK) delivered earnings and revenue surprises of 2.61% and 4.66%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?